Wall Street Signals: AO Group, Inc. (OTC PINK: PAOG) today announced Goldman Small Cap Research has published an initial analyst report covering PAOG’s outlook following two recent acquisitions moving the company into the cannabis biopharma market sector.

AO Group, Inc. (OTC PINK: PAOG) today announced Goldman Small Cap Research has published an initial analyst report covering PAOG’s outlook following two recent acquisitions moving the company into the cannabis biopharma market sector.

 


PAO Group, Inc. (OTC PINK: PAOG) today announced Goldman Small Cap Research has published an initial analyst report covering PAOG’s outlook following two recent acquisitions moving the company into the cannabis biopharma market sector.  The report highlights that recent acquisitions have repositioned PAOG for growth in a sector with market cap valuations as high as $100 million.


Full Goldman Report: Under The Radar, CBD Pharma Player Could Offer Major Upside

Report Highlights:

“Via its recent acquisitions, PAOG has re-positioned itself as an emerging CBD Biopharma company on a development path to treat two major respiratory diseases that each represent billions in potential market sizes.”

“Leveraging a series of favorable studies, the Company is set to engage a CRO to initiate the process for potential FDA approval of RespRx, its new flagship COPD treatment. COPD represents an estimated $14.1B market by 2025.”

“After completing a recent 25 patient study using RespRx to treat COVID-19 symptoms, PAOG is preparing to commence a similar development pathway for this disease.”

“Now that the key acquisitions have been closed, management is preparing to complete corporate, capital markets, and investor relations housekeeping tasks to ensure investors have access to the most recent company financial statements and reports.”

“We should note that a number of CBD Biopharma companies are publicly traded, with market caps ranging as high as $100M or more. Based on our cursory due diligence we found one firm, Avianna (OTC – AVCNF – NR), which is also targeting the COVID-19 arena, which has a current market cap of around $27M. Perhaps as PAOG moves along the development path on either the COPD or COVID-19 track, it can trade toward this figure, assuming current financials and information are available.”

www.paogroupinc.com

­Forward-Looking Statements: Certain announcements in this news delivery may contain forward-peering data inside the significance of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are dependent upon the sheltered harbor made by those standards. All announcements, other than explanations of truth, remembered for this delivery, including, without constraint, proclamations in regards to expected tentative arrangements and goals of the organization are forward-looking articulations that include dangers and vulnerabilities. There can be no confirmation that such explanations will end up being exact and genuine outcomes and future occasions could contrast really from those foreseen in such articulations. Specialized intricacies, which may emerge, could forestall the brief execution of any deliberately huge plan(s) illustrated previously. The Company embraces no obligation to modify or refresh any forward-looking proclamations to reflect occasions or conditions after the date of this delivery.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group